Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and
safety of tenalisib in patients with metastatic TNBC, who have received at least one but not
more than 3 prior therapies in a metastatic setting.